Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Condition: Metastatic Melanoma
MeSH terms: Melanoma
Intervention: High Dose Interleukin-2 (IL-2); ACT with TIL Infusion; Vemurafenib; Lymphodepletion
Intervention description: A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.; Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).; Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.; The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more "space" for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion.
Intervention MeSH terms: Aldesleukin; Cyclophosphamide; Fludarabine; Interleukin-2; Vemurafenib; Enzyme Inhibitors
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 17.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: metastatic; melanoma; cell transfer; ACT; T-cell; immunotherapy; antibodies; lymphocytes

Summary:

      The purpose of this study is to find out more about the effects of an investigational
      combination of medicines, which includes special immune cells (T-cells).

      A T-cell is a type of lymphocyte, or white blood cell. Lymphocytes are a kind of white blood
      cell that protect the body from viral infections, help other cells fight bacterial and fungal
      infections, produce antibodies, fight cancers, and coordinate the activities of other cells
      in the immune system.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Must have unresectable metastatic stage IV melanoma or stage III intransit or regional
             nodal disease and in the opinion of the PI or treating Coinvestigator is an acceptable
             candidate for adoptive cell transfer (ACT).

          -  Residual measurable disease after resection of target lesion(s) for TIL growth

          -  Tumor must have a B-RAF V600E, D or K mutation by pyrosequencing, Cobas assay, or
             equivalent (43)

          -  Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 - 1. ECOG
             performance status of 0-1 will be inferred if the patient's level of energy is ≥ 50%
             of baseline.

          -  May be treatment-naïve or may have been previously treated for metastatic disease.

          -  Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
             within 7 days of starting Vemurafenib.

          -  Adequate renal, hepatic and hematologic function, including creatinine of less than or
             equal to 1.7 gm/dL, total bilirubin less than or equal to 2.0 mg/dL, except in
             patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dL,
             aspartic transaminase (AST) and alanine transaminase (ALT) of less than 3X
             institutional upper limit of normal, hemoglobin of 8 gm/dL or more, white blood count
             (WBC) of 3000 per mcL and total granulocytes of 1000 per mcL or more, and platelets of
             100,000 per mcL or more.

          -  Must have a positive screening Epstein-Barr Virus (EBV) antibody titre on screening
             test

          -  Patients with antibiotic allergies per se are not excluded; although the production of
             TIL for adoptive transfer includes antibiotics, extensive washing after harvest will
             minimize systemic exposure to antibiotics.

          -  At screening, patients with ≤ 3 untreated CNS metastases may be included provided none
             of the untreated lesions are > 1 cm in greatest dimension, and there is no
             peri-tumoral edema present on brain imaging (MRI or CT if MRI is contraindicated).

          -  At screening, patients with ≤ 3 treated central nervous system (CNS) metastases
             treated with either surgical resection and/or radiation therapy may be included.
             Patients may be included if the largest lesion is ≤ 1 cm, and there is no evidence of
             progressive CNS disease on brain imaging at least 28 days after treatment.

          -  At screening, may be included if the largest lesion is > 1 cm or > 3 in number, and
             there is no evidence of progressive CNS disease on brain imaging at least 90 days
             after treatment with surgery and/or radiation therapy.

          -  At screening, must have no known history of congenital long QT syndrome and must have
             a corrected mean QTc interval ≤ 450 msec at baseline.

          -  No evidence of ongoing cardiac dysrhythmia ≥ grade 2, NCI Common Terminology Criteria
             for Adverse Events (CTCAE) v4.0

          -  All laboratory and imaging studies must be completed and satisfactory within 30 days
             of signing the consent document, with the exceptions of: negative serum pregnancy test
             for WOCBP must be negative within 7 days of starting Vemurafenib, human leukocyte
             antigen (HLA) typing which will not be repeated if performed previously, and pulmonary
             function tests/cardiac stress tests whose results are valid for 6 months if performed
             previously.

        Exclusion Criteria:

          -  Patients with active systemic infections requiring intravenous antibiotics,
             coagulation disorders or other major medical illness of the cardiovascular,
             respiratory or immune system, which in the opinion of the principal investigator (PI)
             or treating co-investigator is not acceptable risk for ACT, are excluded.

          -  Patients testing positive for HIV titre, Hepatitis B surface antigen, Hepatitis B core
             antibody, Hepatitis C antibody, human T-cell lymphotropic virus type (HTLV) I or II
             antibody, or both rapid plasma reagin (RPR) and fluorescent treponemal antibodies
             (FTA) positive

          -  Patients who are pregnant or nursing

          -  Patients needing chronic, immunosuppressive systemic steroids are excluded

          -  Patients with autoimmune diseases that require immunosuppressive medications

          -  Presence of a significant psychiatric disease, which in the opinion of the principal
             investigator or his designee, would prevent adequate informed consent or render
             immunotherapy unsafe or contraindicated

          -  Patients with > 3 untreated CNS metastases or evidence of peri-tumoral edema

          -  Patients with ≤ 3 untreated CNS metastases but with at least one lesion >1 cm or
             peri-tumoral edema

          -  Patients with congenital long QT syndrome

          -  Patients with invasive malignancy other than melanoma at the time of enrollment and
             within 2 years prior to the first Vemurafenib administration are excluded, except for
             adequately treated (with curative intent) basal or squamous cell carcinoma of the
             skin, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in
             situ prostate cancer, or limited stage bladder cancer or other cancers from which the
             patient has been disease-free for at least 2 years.

          -  Unable to swallow pills

          -  Patients with treated CNS metastases > 1 cm or > 3 in number will be excluded if there
             is evidence of progressive CNS disease on brain imaging at least 90 days after
             treatment with surgery and/or radiation therapy.

          -  Unable to comprehend and give informed consent

          -  Previous BRAF inhibitor treatment

          -  Male patients with female partners of childbearing potential who do not agree to use 2
             FDA-accepted forms of contraception during sexual intercourse with women of
             child-bearing potential from the start of Vemurafenib and up to at least 6 months
             after discontinuing Vemurafenib

          -  WOCBP who do not agree to use 2 FDA forms of contraception during sexual intercourse
             from the start of Vemurafenib and up to at least 6 months after discontinuing
             Vemurafenib